

Biologics Symposium 2026 – Dutch edition

Designing tomorrow's therapies

Date: June 2, 2026

Location: Accelerator Building – Utrecht

Preliminary Program

8.00 – 8.45	Registration & posters setup
8.45 – 9.00	Welcome & intro from the organizers Ilse Roodink (CSO, AVS Bio) & Adele Hannigan (CBO, RoukenBio)
9.00 – 13.00	Morning session
9.00 – 10.40	Scalable, robust and easy to use antibody engineering with Generative AI Néstor Vázquez Bernat (Scientific Solutions Consultant, Cradle)
	AbDirect: Protein-Centric Discovery of High-Potency Human Antibodies from Patient Serum Maurits den Boer (CEO, Abvion Biologics B.V.)
	Immortalized patients' derived B cell libraries for the interrogation and unbiased discovery of novel therapeutic targets and antibodies Casper Marsman (Senior Scientist, Kling Biotherapeutics)
	Expediting lead antibody generation leveraging a multiparametric platform delivering data-rich outputs Ilse Roodink (CSO, AVS Bio)
10.40 – 11.10	Coffee break – Networking & poster session
11.10 – 11.40	<i>Fireside chat</i> - De-risking drug development strategic, experimental and regulatory aspects Erik Doevendans (Principal Consultant, Doevendans Consultancy), Adele Hannigan (CBO, RoukenBio), Ilse Roodink (CSO, AVS Bio), Louis Boon (CSO, JJP Biologics)
11.40 – 13.00	Discovery and development of Click-to-Release ADCs with enhanced therapeutic potential. Lars Guelen (Head of Biology, Tagworks)
	Showcasing Preclinical Development of Byondis' Antifolate Linker-Drug ADCs. Renier Heijkants (Principal Scientist, Byondis)
	A PLK1/ BET degrader antibody conjugate for the treatment of TROP2 expressing cancers Joost Uitdehaag (Head of Biology, Crossfire Oncology)
13.00 – 14.00	Lunch – Networking & poster session

14-00 – 18.00	Afternoon session Chairman: RoukenBio
14.00 – 14.30	<i>Fireside chat - From innovation to impact: financing and scaling the next wave of biologics</i> Jana Obajdin (BGV), Valentina Vignali (Utrecht Holdings), Floris Hamel (BOM), Charlotte Koldeweij (Forbion)
14.30 – 16.10	From Lab to Clinic: The TargED story Kristof Vercruysse (CEO, TargED)
	First-in-class T Cell Engagers targeting intracellular proteins through peptide:HLA targeting Jan-Jaap Verhoef (CEO & Founder, Imuno Therapeutics)
	Rationally engineered T cell therapies for high-need solid tumor indications Marleen van Loenen (Executive Director, Head of Discovery, T-Knife)
	Designing Biologics in Biological Context Agapitos Patakas (CSO, RoukenBio)
16.10 – 16.40	Coffee break – Networking & poster session
16.40 – 17.55	Antibody Format Discovery @ Genmab: The Past, Present, and Future Bart-Jan de Kreuk (Associate Director, Antibody Format Discovery – Genmab)
	Every disadvantage has its advantage – JJP-1008 as a novel checkpoint inhibitor for the treatment of HVEM-positive cancers Louis Boon (CSO, JJP Biologics)
	SureTACs: expanding the biologics toolbox through cell surface protein degradation Madelon Maurice (Full Professor at UMC Utrecht and co-founder of Laigo Bio)
17.55 – 18.00	Conclusions Ilse Roodink (CSO, AVS Bio) & Adele Hannigan (CBO, RoukenBio)
18.00 – 19.00	Bites & Drinks